ImmunityBio, Inc.'s advances with Anktiva & rBCG show promise amid financial hurdles. Click here to find out why IBRX stock ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: SES AI Corp (SES) 118.91% +9.28, Microvision ...

The United States market has experienced a flat performance over the last week, yet it has seen an 8.4% rise over the past year, with earnings forecasted to grow by 14% annually. In this context of ...

Teacher Retirement System of Texas grew its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 20.4% in the ...

CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report issued on Monday,Benzinga reports. They currently have a $30.00 target price on the stock.